Global and Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, Status and Forecast 2023-2027

Report ID: 1014729 | Published Date: Jan 2025 | No. of Page: 99 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Pertuzumab
        1.2.3 Trastuzumab
    1.3 Market by Application
        1.3.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Combination Therapy
        1.3.3 Mono Therapy
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Perspective (2016-2027)
    2.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Growth Trends by Regions
        2.2.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Historic Market Share by Regions (2016-2021)
        2.2.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecasted Market Size by Regions (2022-2027)
    2.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Industry Dynamic
        2.3.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Trends
        2.3.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Drivers
        2.3.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Challenges
        2.3.4 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players by Revenue
        3.1.1 Global Top Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players by Revenue (2016-2021)
        3.1.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Players (2016-2021)
    3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue
    3.4 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Concentration Ratio
        3.4.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in 2020
    3.5 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Key Players Head office and Area Served
    3.6 Key Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Solution and Service
    3.7 Date of Enter into Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Breakdown Data by Type
    4.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Historic Market Size by Type (2016-2021)
    4.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecasted Market Size by Type (2022-2027)

5 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Breakdown Data by Application
    5.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Historic Market Size by Application (2016-2021)
    5.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2016-2027)
    6.2 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type
        6.2.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021)
        6.2.2 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027)
        6.2.3 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2027)
    6.3 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application
        6.3.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021)
        6.3.2 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027)
        6.3.3 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2027)
    6.4 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country
        6.4.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2016-2021)
        6.4.2 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2016-2027)
    7.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type
        7.2.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021)
        7.2.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027)
        7.2.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2027)
    7.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application
        7.3.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021)
        7.3.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027)
        7.3.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2027)
    7.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country
        7.4.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2016-2021)
        7.4.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2016-2027)
    8.2 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type
        8.2.1 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2027)
    8.3 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application
        8.3.1 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2027)
    8.4 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region
        8.4.1 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2016-2027)
    9.2 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type
        9.2.1 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021)
        9.2.2 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027)
        9.2.3 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2027)
    9.3 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application
        9.3.1 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021)
        9.3.2 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027)
        9.3.3 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2027)
    9.4 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country
        9.4.1 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2016-2021)
        9.4.2 Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2016-2027)
    10.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type
        10.2.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2027)
    10.3 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application
        10.3.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2027)
    10.4 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country
        10.4.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Details
        11.1.2 Roche Business Overview
        11.1.3 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
        11.1.4 Roche Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
        11.1.5 Roche Recent Development
    11.2 BOC Sciences
        11.2.1 BOC Sciences Company Details
        11.2.2 BOC Sciences Business Overview
        11.2.3 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
        11.2.4 BOC Sciences Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
        11.2.5 BOC Sciences Recent Development
    11.3 LGM Pharma
        11.3.1 LGM Pharma Company Details
        11.3.2 LGM Pharma Business Overview
        11.3.3 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
        11.3.4 LGM Pharma Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
        11.3.5 LGM Pharma Recent Development
    11.4 Biotechnica Pharma Global
        11.4.1 Biotechnica Pharma Global Company Details
        11.4.2 Biotechnica Pharma Global Business Overview
        11.4.3 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
        11.4.4 Biotechnica Pharma Global Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
        11.4.5 Biotechnica Pharma Global Recent Development
    11.5 KinBio
        11.5.1 KinBio Company Details
        11.5.2 KinBio Business Overview
        11.5.3 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
        11.5.4 KinBio Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
        11.5.5 KinBio Recent Development
    11.6 Merck
        11.6.1 Merck Company Details
        11.6.2 Merck Business Overview
        11.6.3 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
        11.6.4 Merck Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
        11.6.5 Merck Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Pertuzumab
    Table 3. Key Players of Trastuzumab
    Table 4. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Regions (2016-2021)
    Table 8. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Regions (2022-2027)
    Table 10. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Trends
    Table 11. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Drivers
    Table 12. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Challenges
    Table 13. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Restraints
    Table 14. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Players (2016-2021)
    Table 16. Global Top Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer as of 2020)
    Table 17. Ranking of Global Top Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Solution and Service
    Table 21. Date of Enter into Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type (2016-2021)
    Table 25. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Application (2016-2021)
    Table 29. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2016-2021) & (US$ Million) 
    Table 36. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2022-2027) & (US$ Million) 
    Table 37. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2016-2021) & (US$ Million) 
    Table 42. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2022-2027) & (US$ Million) 
    Table 43. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2016-2021) & (US$ Million) 
    Table 48. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2022-2027) & (US$ Million) 
    Table 49. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2016-2021) & (US$ Million) 
    Table 54. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2022-2027) & (US$ Million) 
    Table 55. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2016-2021) & (US$ Million) 
    Table 60. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2022-2027) & (US$ Million) 
    Table 61. Roche Company Details
    Table 62. Roche Business Overview
    Table 63. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
    Table 64. Roche Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021) & (US$ Million)
    Table 65. Roche Recent Development
    Table 66. BOC Sciences Company Details
    Table 67. BOC Sciences Business Overview
    Table 68. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
    Table 69. BOC Sciences Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021) & (US$ Million)
    Table 70. BOC Sciences Recent Development
    Table 71. LGM Pharma Company Details
    Table 72. LGM Pharma Business Overview
    Table 73. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
    Table 74. LGM Pharma Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021) & (US$ Million)
    Table 75. LGM Pharma Recent Development
    Table 76. Biotechnica Pharma Global Company Details
    Table 77. Biotechnica Pharma Global Business Overview
    Table 78. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
    Table 79. Biotechnica Pharma Global Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021) & (US$ Million)
    Table 80. Biotechnica Pharma Global Recent Development
    Table 81. KinBio Company Details
    Table 82. KinBio Business Overview
    Table 83. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
    Table 84. KinBio Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021) & (US$ Million)
    Table 85. KinBio Recent Development
    Table 86. Merck Company Details
    Table 87. Merck Business Overview
    Table 88. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product
    Table 89. Merck Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021) & (US$ Million)
    Table 90. Merck Recent Development
    Table 91. Research Programs/Design for This Report
    Table 92. Key Data Information from Secondary Sources
    Table 93. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Type: 2020 VS 2027
    Figure 2. Pertuzumab Features
    Figure 3. Trastuzumab Features
    Figure 4. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Application: 2020 VS 2027
    Figure 5. Combination Therapy Case Studies
    Figure 6. Mono Therapy Case Studies
    Figure 7. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Report Years Considered
    Figure 8. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 9. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 10. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Regions: 2020 VS 2027
    Figure 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Regions (2022-2027)
    Figure 12. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Players in 2020
    Figure 13. Global Top Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer as of 2020
    Figure 14. The Top 10 and 5 Players Market Share by Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in 2020
    Figure 15. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type (2016-2021)
    Figure 16. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Type (2022-2027)
    Figure 17. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 18. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Type (2016-2027)
    Figure 19. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Application (2016-2027)
    Figure 20. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Country (2016-2027)
    Figure 21. United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Type (2016-2027)
    Figure 25. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Application (2016-2027)
    Figure 26. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Country (2016-2027)
    Figure 27. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. U.K. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Nordic Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Type (2016-2027)
    Figure 35. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Application (2016-2027)
    Figure 36. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Region (2016-2027)
    Figure 37. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. South Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Type (2016-2027)
    Figure 45. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Application (2016-2027)
    Figure 46. Latin America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Country (2016-2027)
    Figure 47. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Type (2016-2027)
    Figure 51. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Application (2016-2027)
    Figure 52. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Country (2016-2027)
    Figure 53. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Saudi Arabia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. UAE Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Roche Revenue Growth Rate in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
    Figure 57. BOC Sciences Revenue Growth Rate in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
    Figure 58. LGM Pharma Revenue Growth Rate in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
    Figure 59. Biotechnica Pharma Global Revenue Growth Rate in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
    Figure 60. KinBio Revenue Growth Rate in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
    Figure 61. Merck Revenue Growth Rate in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2016-2021)
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Roche
BOC Sciences
LGM Pharma
Biotechnica Pharma Global
KinBio
Merck
Frequently Asked Questions
Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports